Functionalized Bioink Delivering Biomolecules for the Treatment of Craniofacial Diseases

NCT ID: NCT06533150

Last Updated: 2025-03-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 180 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-07
• Study Completion Date: 2026-10-01

Brief Summary

The study aims to address the challenges of craniofacial bone reconstruction in pediatric and adult patients affected by congenital craniofacial malformations (i.e. craniosynostosis), trauma or tumors, by developing an innovative biohybrid material with tunable rheological properties, serving as a sealing agent and defect filler. Craniectomy/craniotomy procedures often leave bone defects that require cranioplasty to protect the underlying dura mater and the brain from physical insults. Reconstruction of the viscerocranial skeleton poses additional challanges, due to the complex anatomy of the facial skull and significant esthetic and functional demands on its reconstruction.

The study plans to develop a mouldable biosynthetic gelatin-methacrylamide (GelMA)-based hydrogel complexed with functionalized Poly (lactic-co-glycolic acid) (PLGA) nanoparticles for drug delivery. Osteoprogenitors cells (including mesenchymal stromal cells/osteoblasts and monocytes/osteoclasts) will be isolated from bone tissue fragments of enrolled patients and peripheral blood sample, respectively, to obtain 2D and 3D cultures mimicking the in vivo bone environment. High-throughput profiling of patients' samples will identify druggable targets for the bioactive compounds to be released by the bioink. In vitro validation will involve osteoprogenitor co-cultures derived from patients to assess uptake, release dynamics, biocompatibility, immunogenicity, and therapeutic effects of the developed complex. The final goal will be to develop a pre-prototype tissue engineering biocomposite for craniofacial bone reconstruction.

Detailed Description

To develop a mouldable biosynthetic collagen-based polymer matrix, commercial gelatin-methacrylamide (GelMA)-based hydrogels will be biochemically modified to finely tune their pseudo-plasticity and yield stress, and functionalized to implement drug delivery for improved biological properties. The GelMA will be chemically enriched with: adhesive molecules (e.g. alginate-based or ion releasing inorganic compounds), if needed, to increase the adhesion to implantable materials used in craniofacial reconstruction, thiol-based non- cleavage-type photoinitiators (e.g. eosinY combined with triethanolamine and vinyl caprolactam) to enable visible light-activated crosslinking and minimize the safety concerns of UV light. Photo-crosslinking will be achieved through a portable visible light device (420-480 nm) to induce the jellification of the bioink. The physical properties (morphology, viscoelastic properties, stiffness, resistance to an applied stress) of the different GelMA compounds will be analyzed according to standardized procedures. The adhesive properties of the GelMA will be measured by lap-shear strength tests in dry conditions. Once identified GelMA compounds showing the highest biological features, this will be endowed with functionalized Poly (lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs).

To this aim, biocompatible PLGA-Polyethylene glycol (PEG) NPs will be synthesized and functionalized with bis-sulfone for binding targeting moieties on the surface. The synthesis involves PLGA activation, PLGA-PEG conjugation, bis-sulfone activation, and PLGA-PEG-bis-sulfone conjugation. The PLGA/PEG ratio will be adjusted for the hydrophobicity/hydrophilicity payload. Bis-sulfone is used for selective and efficient PEGylation of protein's disulfide bond or to conjugate His-tagged protein/peptides according to standardized methods to implement either specific cell targeting or antimicrobial agents. High performance liquid chromatography (HPLC) will be used to validate the biosynthetic reaction. Dynamic Light Scattering (DLS), Nanoparticle Tracking Analysis (NTA), and Scanning electron microscopy (SEM) will define the morphological and ultrastructural properties of the final construct. Surface Plasmon Resonance will validate target recognition. Then, GelMA-NP hybrid compound assembly will be achieved through extrusion 3D printing according to standardized production pipelines. The hydrogel and the NP suspension will be dispensed through separate nozzles, in 2D and 3D patterns with 100-1000 nm feature sizes, under pressure and temperature control. Scalar NP concentrations will be used and then evaluated.

NP integrity and release dynamics of these from GelMA will be studied by submerging the GelMA-NPs loaded with fluorescent compound with a bio-mimetic cell growth medium and quantifying the NPs released in the supernatant in time course experiments. NP quantification will be performed using UV-Vis Spectroscopy, Fluorescence Spectroscopy or particle counting such as NTA system. NPs integrity will be studied with transmission electron microscopy (TEM) and DLS.

Once biochemically characterized GelMA-NPs, these will be used to deliver bioactive compounds identified through proteomics data as subsequently described.

To validate the developed bio-ink in in vitro craniofacial disease models, patients with craniofacial malformations undergoing cranial surgery will be selected and enrolled in the study. Specifically, paediatric patients affected by craniosynostosis and other inborn defects, trauma or brain tumors undergoing cranial surgery will be enrolled. Adult patients undergoing craniofacial surgery will be also selected and enrolled for craniofacial trauma and tumors. To this purpose, cranial bone tissue specimens derived from both paediatric and adult patients will be obtained as surgical waste during craniectomy or cranial vault remodeling upon obtaining the signed informed consent (by parents in case of children). For each patient, the waste tissues will be randomized into three aliquots. Of these, 1 aliquot will be collected in cell growth medium for seeding bone tissue samples into culture plate to isolate mesenchymal stromal cells (MSCs). Thereafter, MSC will be expanded up to the 3rd culture passage and collected in biobanking infrastructures with associated anonymized clinical data and optimized tracking system for subsequent analysis as follows. GelMA-based bioink NP release and biocompatibility will be analyzed using MSC, through functional assays to: evaluate focal adhesion dynamics and study cell adhesion to the gelified bioink by immunofluorescence assay. Cell behaviors and viability will be measured in time course experiments using a live cell imaging system (Incucyte Live Cells Analysis systems).

In addition, 2 aliquots of patients-derived bone tissue specimens will be snap-frozen in liquid nitrogen (after submerging it in cryoprotective medium with protease inhibitors). Proteins and metabolites will be isolated from these samples using in-house standardized protocol. Extracted samples will be then digested using Filter-aided sample preparation (FASP) digestion protocol. Then, samples will be analysed by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Then, obtained results on proteins and metabolites will be analysed by integrated pathway analysis (using IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. Computational drug design tools, including molecular docking and virtual screening, will be employed to identify the lead compounds from drug/chemical databases capable of interacting with the selected targets from the integrated omic profile datasets. The dynamic behavior, stability, and binding interactions of target-ligand complexes will be studied through Molecular dynamics (MD) simulations to analyze binding motifs and hotspots. MD-informed insights on molecular interactions will guide the design and optimization of novel compounds. This will involve incorporating structural modifications with ligand-based approaches, and performing virtual screening to enhance binding affinity, selectivity, and drug-likeness. The biomolecules identified through these in silico studies will be then commercially purchased and encapsulated in PLGA NPs. In this regard, nanoprecipitation and single emulsion will be exploited for hydrophobic payloads, while double-emulsion solvent evaporation technique (w1/o/w2) will be employed for hydrophilic payloads. After, PLGA delivering selected compounds will be complexed into hydrogel (GelMA) matrix. The functional trophic and pro-regenerative properties of the bioink compound delivering biomolecules will be assessed in MSC to test osteogenic properties - through ALP activity assay, in vitro mineralization staining and marker gene expression analysis. In addition, human umbilical vein endothelial cells (commercial line) will be treated with GelMA-NPs-drug complex for evaluating the angiogenic properties by counting and sizing the capillary-like structures formed in vitro (tube formation assay).

In addition, a small aliquot of peripheral venous blood (2-3 ml for pediatric patients and up to 7 ml for adult patients) from routine clinical examinations will be collected. PBMCs will be isolated from whole blood sample using Ficoll density gradient centrifugation technique. Monocyte/macrophage cells will be then separated through CD14 antibody-conjugated magnetic beads and cultured in vitro with factors (i.e. M-CSF, RANKL) to form mature osteoclasts. These will be used to evaluate the bio-resorbability of GelMA-NP compound. Briefly, osteoclasts will be seeded on the GelMA-NP nanopatterned surfaces and the expression of typical osteoclast-specific markers will be assessed through immunofluorescence analysis. SEM and immunofluorescence assay will be used to visualize ultra-structurally the osteoclast-bioink interface and discriminate resorption two- and three-dimensionally.

MSC/osteoprogenitors and osteoclasts derived from patients will be also exploited to obtain 2D and 3D in vitro culture to mimic the biological microenviroment existing at the bone-implant boundary for the validation of the developed bioink complex. The bioink components will be either bioprinted with cells (i.e. cells delivered through an independent nozzle) to form cell-laden models, or printed on the growth surface of cell culture vessels and let jelify before cell seeding, according to the aims of each test. The release dynamics of NP from the GelMA, cell viability and proliferation, angiogenic and bone regenerative effects will be assessed as mentioned above.

To test its antibacterial effects, both the unloaded GelMA and the GelMA-NP will be printed on to petri dishes and let jelify. Thereafter it will be incubated with the opportunistic bacterial strains (E. coli, S. aureus, Streptococcus mutans, Enterococcus faecalis and Pseudomonas aeruginosa) in the appropriate culture broth overnight. Bacterial adhesion and count will be assessed comparatively, testing dose- and time-related effects. Antibacterial activity of GelMA-NP over GelMA, will be also supported by SEM imaging.

Conditions

Craniofacial Defects, Subtle; Skull Defect; Craniosynostoses

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

multiomic profiling

2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Paediatric patients (0-3 years) undergoing surgery for craniosynostosis and other inborn defects/trauma/brain tumors
• Adult patients (18-50 years) undergoing craniofacial surgery for (mainly) trauma and tumours

Exclusion Criteria

• Paediatric patients older than 3 years of age
• Adults older than 50 years of age
• Paediatric patients and adult patients with other cranial diseases
• Patients with cranial defects that do not require craniofacial surgery

• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Luca Massimi

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Locations

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC neurochirurgia Infantile

Roma, , Italy

Countries

Italy

Other Identifiers

6830

Identifier Type: -

Identifier Source: org_study_id